Total Payments
$392,793
2024 Payments
$26,846
Companies
22
Transactions
242
Medicare Patients
4,837
Medicare Billing
$232,070
Payment Breakdown by Category
Consulting$229,832 (58.5%)
Research$91,870 (23.4%)
Other$44,168 (11.2%)
Travel$22,277 (5.7%)
Food & Beverage$4,512 (1.1%)
Education$133.90 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $229,832 | 97 | 58.5% |
| Unspecified | $91,870 | 10 | 23.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,153 | 20 | 9.5% |
| Travel and Lodging | $22,277 | 53 | 5.7% |
| Honoraria | $7,000 | 2 | 1.8% |
| Food and Beverage | $4,512 | 58 | 1.1% |
| Education | $133.90 | 1 | 0.0% |
| Grant | $15.98 | 1 | 0.0% |
Payments by Type
General
$300,923
232 transactions
Research
$91,870
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $90,575 | 2 | $0 (2018) |
| Boston Scientific Corporation | $82,008 | 88 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $40,789 | 24 | $0 (2023) |
| Janssen Research & Development, LLC | $34,150 | 6 | $0 (2023) |
| PFIZER INC. | $34,114 | 20 | $0 (2023) |
| EKOS Corporation | $21,365 | 11 | $0 (2019) |
| Amgen Inc. | $17,086 | 17 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $16,888 | 17 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $10,195 | 6 | $0 (2021) |
| Merck Sharp & Dohme LLC | $8,795 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,846 | 35 | Boston Scientific Corporation ($23,151) |
| 2023 | $28,542 | 29 | Boston Scientific Corporation ($12,143) |
| 2022 | $57,835 | 48 | Boston Scientific Corporation ($24,626) |
| 2021 | $49,132 | 18 | Janssen Research & Development, LLC ($21,125) |
| 2020 | $49,321 | 31 | E.R. Squibb & Sons, L.L.C. ($24,999) |
| 2019 | $28,657 | 33 | Janssen Pharmaceuticals, Inc ($7,350) |
| 2018 | $73,179 | 28 | Eli Lilly and Company ($38,360) |
| 2017 | $79,281 | 20 | Eli Lilly and Company ($52,215) |
All Payment Transactions
242 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Penumbra, Inc. | Indigo System (Device) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: Peripheral Intervention | ||||||
| 12/19/2024 | Boston Scientific Corporation | EkoSonic (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: EkoSonic_PI | ||||||
| 12/19/2024 | Boston Scientific Corporation | EkoSonic (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: EkoSonic_PI | ||||||
| 12/02/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: General - Therapies_PI | ||||||
| 11/04/2024 | Boston Scientific Corporation | EkoSonic (Device) | Food and Beverage | In-kind items and services | $52.80 | General |
| Category: EkoSonic_PI | ||||||
| 11/03/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $102.50 | General |
| Category: General - Therapies_PI | ||||||
| 11/01/2024 | Boston Scientific Corporation | EkoSonic (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: EkoSonic_PI | ||||||
| 11/01/2024 | Boston Scientific Corporation | EkoSonic (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: EkoSonic_PI | ||||||
| 10/09/2024 | Penumbra, Inc. | Indigo System (Device) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Peripheral Intervention | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $369.55 | Research |
| Study: A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH) | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $235.50 | Research |
| Study: A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH) | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $91.71 | Research |
| Study: A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH) | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $53.93 | Research |
| Study: A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH) | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $39.62 | Research |
| Study: A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH) | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $15.41 | Research |
| Study: A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH) | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $15.41 | Research |
| Study: A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH) | ||||||
| 09/26/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $473.71 | Research |
| Study: A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH) | ||||||
| 09/12/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $267.38 | General |
| Category: General - Therapies_PI | ||||||
| 09/05/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $9,800.00 | General |
| Category: General - Therapies_PI | ||||||
| 09/05/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: General - Therapies_PI | ||||||
| 09/05/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: General - Therapies_PI | ||||||
| 08/02/2024 | Boston Scientific Corporation | JETSTREAM SC (Device) | Travel and Lodging | In-kind items and services | $71.43 | General |
| Category: JETSTREAM_PI | ||||||
| 08/02/2024 | Boston Scientific Corporation | JETSTREAM SC (Device) | Food and Beverage | In-kind items and services | $43.41 | General |
| Category: JETSTREAM_PI | ||||||
| 08/01/2024 | Boston Scientific Corporation | JETSTREAM SC (Device) | Travel and Lodging | In-kind items and services | $491.86 | General |
| Category: JETSTREAM_PI | ||||||
| 08/01/2024 | Boston Scientific Corporation | JETSTREAM SC (Device) | Food and Beverage | In-kind items and services | $335.82 | General |
| Category: JETSTREAM_PI | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| THE EFFECT OF DULAGLUTIDE ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES - RESEARCHING CARDIOVASCULAR EVENTS WITH A WEEKLY INCRETIN IN DIABETES - REWIND | Eli Lilly and Company | $90,575 | 2 |
| A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH) | Regeneron Pharmaceuticals, Inc. | $1,295 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 1,246 | 1,529 | $371,376 | $70,673 |
| 2022 | 7 | 1,229 | 1,447 | $281,459 | $57,557 |
| 2021 | 10 | 1,272 | 1,510 | $282,186 | $61,588 |
| 2020 | 11 | 1,090 | 1,324 | $196,638 | $42,253 |
Total Patients
4,837
Total Services
5,810
Medicare Billing
$232,070
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 212 | 262 | $156,938 | $29,191 | 18.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 79 | 79 | $63,279 | $10,777 | 17.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 69 | 69 | $55,545 | $10,114 | 18.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 68 | $28,288 | $6,851 | 24.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 719 | 904 | $30,736 | $6,081 | 19.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 57 | $16,530 | $3,818 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 29 | 32 | $12,916 | $2,402 | 18.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 14 | 14 | $5,648 | $1,150 | 20.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 44 | 44 | $1,496 | $288.12 | 19.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 157 | 174 | $102,258 | $20,601 | 20.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 71 | 71 | $56,499 | $12,005 | 21.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 62 | 62 | $46,362 | $9,747 | 21.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 776 | 931 | $32,380 | $6,475 | 20.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 47 | 73 | $20,876 | $4,447 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 37 | $14,673 | $2,623 | 17.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 27 | 40 | $6,370 | $1,271 | 20.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2022 | 59 | 59 | $2,041 | $388.40 | 19.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 105 | 107 | $87,339 | $18,238 | 20.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 119 | 136 | $66,969 | $16,146 | 24.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 83 | 134 | $39,290 | $8,271 | 21.1% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 801 | 946 | $33,110 | $6,706 | 20.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 40 | 40 | $28,185 | $6,306 | 22.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 25 | 26 | $8,890 | $2,002 | 22.5% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 34 | 54 | $8,640 | $1,758 | 20.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 12 | 12 | $4,164 | $1,047 | 25.2% |
About Dr. Gregory Piazza, M.D
Dr. Gregory Piazza, M.D is a Cardiovascular Disease healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326006818.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Piazza, M.D has received a total of $392,793 in payments from pharmaceutical and medical device companies, with $26,846 received in 2024. These payments were reported across 242 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($229,832).
As a Medicare-enrolled provider, Piazza has provided services to 4,837 Medicare beneficiaries, totaling 5,810 services with total Medicare billing of $232,070. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Boston, MA
- Active Since 05/03/2006
- Last Updated 05/07/2012
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1326006818
Products in Payments
- TRULICITY (Drug) $90,575
- XARELTO (Drug) $54,937
- ELIQUIS (Drug) $34,934
- EKOSONIC (Device) $22,168
- General - Therapies (Device) $16,771
- Repatha (Biological) $15,719
- EkoSonic (Device) $14,590
- GENERAL - VASCULAR INTERVENTION (Device) $8,250
- Twirla (Drug) $6,150
- GARDASIL (Biological) $5,135
- General - Vascular Intervention (Device) $4,745
- Indigo System (Device) $4,500
- GENERAL THERAPIES (Device) $4,076
- BEVYXXA (Drug) $3,276
- GENERAL VASCULAR INTERVENTION (Device) $2,500
- Angel Catheter (AC3930A) (Device) $2,051
- On-X (Device) $2,025
- JETSTREAM SC (Device) $1,229
- ELUVIA (Device) $1,155
- GENERAL VASCULAR INTERVENTION (Device) $1,066
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Boston
Dr. Elizabeth Nabel, M.d, M.D
Cardiovascular Disease — Payments: $3.0M
Cardiovascular Disease $3.0M
Kenneth Rosenfield, M.d, M.D
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Eric Secemsky, Md, Msc, MD, MSC
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Benjamin Scirica, M.d, M.D
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Jorge Plutzky, Md, MD
Cardiovascular Disease — Payments: $973,823
Cardiovascular Disease $973,823
Christopher Cannon, Md, MD
Cardiovascular Disease — Payments: $869,405
Cardiovascular Disease $869,405